Mr Jon Mowles, Sector Specialist, Life Sciences Investment Organization, UK Trade & Investment (Photo Courtesy: www.tecnologia.publicacionmedica.com)
He became the general manager and UK director at BioChem Pharma prior to working as an independent management consultant for Swiss, French, US and Japanese biotech companies.
Later, he co-founded two UK-based biotechnology companies. He currently works for UK Trade and Investment (UKTI) as a Life Sciences Sector Specialist.
Q: Can you share insights into the work happening in the area of oncology?
Mr Jon Mowles: Government sponsored organizations encourage the uptake of clinical trials. Indian companies want to come to the UK and collaborate with these organizations.
Also, now we are witnessing a successful track record of recruiting patients for clinical trials. We have more patients now in the area of oncology clinical trials in the UK than anywhere else in Europe.
Q: About a million new cancer cases are reported in India every year. How can the UK oncology companies leverage this and create mutual benefits to both India and the UK?